Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study
Authors:
- Nicolas MarincekNMNicolas Marincek
- Ann-Catherine JörgAJAnn-Catherine Jörg
- Philippe BrunnerPBPhilippe Brunner
- Christian SchindlerCSChristian Schindler
- Michael T KollerMKMichael T Koller
- Christoph RochlitzCRChristoph Rochlitz
- Jan Müller-BrandJMJan Müller-Brand
- Helmut R MaeckeHMHelmut R Maecke
- Matthias BrielMBMatthias Briel
- Martin A WalterMartin A Walter
Open Access
- 15 January 2013
- journal article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 11 (1) , 17
Abstract
Background: We describe the long-term outcome after clinical introduction and dose escalation of somatostatin receptor targeted therapy with [90Y-DOTA]-TOC in patients with metastasized neuroendocrine tumors. Methods: In a clinical phase I dose escalation study we treated patients with increasing [90Y-DOTA]-TOC activities. Multivariable Cox regression and competing risk regression were used to compare efficacy and toxicities of the different dosage protocols. Results: Overall, 359 patients were recruited; 60 patients were enrolled for low dose (median: 2.4 GBq/cycle, range 0.9-7.8 GBq/cycle), 77 patients were enrolled for intermediate dose (median: 3.3 GBq/cycle, range: 2.0-7.4 GBq/cycle) and 222 patients were enrolled for high dose (median: 6.7 GBq/cycle, range: 3.7-8.1 GBq/cycle) [90Y-DOTA]-TOC treatment. The incidences of hematotoxicities grade 1–4 were 65.0%, 64.9% and 74.8%; the incidences of grade 4/5 kidney toxicities were 8.4%, 6.5% and 14.0%, and the median survival was 39 (range: 1–158) months, 34 (range: 1–118) months and 29 (range: 1–113) months. The high dose protocol was associated with an increased risk of kidney toxicity (Hazard Ratio: 3.12 (1.13-8.59) vs. intermediate dose, p = 0.03) and a shorter overall survival (Hazard Ratio: 2.50 (1.08-5.79) vs. low dose, p = 0.03). Conclusions: Increasing [90Y-DOTA]-TOC activities may be associated with increasing hematological toxicities. The dose related hematotoxicity profile of [90Y-DOTA]-TOC could facilitate tailoring [90Y-DOTA]-TOC in patients with preexisting hematotoxicities. The results of the long-term outcome suggest that fractionated [90Y-DOTA]-TOC treatment might allow to reduce renal toxicity and to improve overall survival. Trial registration: ClinicalTrials.gov number:NCT00978211Keywords
This publication has 29 references indexed in Scilit:
- Competing risks and the clinical community: irrelevance or ignorance?Statistics in Medicine, 2011
- Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- Peptide Receptor Radionuclide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Advanced Neuroendocrine Tumors: Results from a Danish Cohort Treated in SwitzerlandNeuroendocrinology, 2011
- [90Yttrium‐DOTA]‐TOC response is associated with survival benefit in iodine‐refractory thyroid cancerCancer, 2009
- Response to [90Yttrium-DOTA]-TOC Treatment is Associated with Long-term Survival Benefit in Metastasized Medullary Thyroid Cancer: A Phase II Clinical TrialClinical Cancer Research, 2007
- Tutorial in biostatistics: competing risks and multi‐state modelsStatistics in Medicine, 2006
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- DOTATOC: A powerful new tool for receptor-mediated radionuclide therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 1997
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982
- The Pharmacology and Toxicology of the Bone SeekersAnnual Review of Pharmacology, 1961